MedPath

Open Label Pharmacokinetic in Adult Patients With Ventilator-Associated Pneumonia

Phase 1
Terminated
Conditions
Ventilator Associated Pneumonia
Interventions
Registration Number
NCT00771719
Lead Sponsor
Basilea Pharmaceutica
Brief Summary

The purpose of this research study is to measure the levels of ceftobiprole in the blood, urine and tissues of the lungs during and after administration of four doses of ceftobiprole. Safety of the drug will also be evaluated.

Detailed Description

Patients will receive a intravenous dose of ceftobiprole infused over 4 hours. Multiple blood samples will be obtained to determine the concentration of Ceftobiprole in the blood. Bronchoalveolar lavage (BAL) samples will be collected to determine the concentration of ceftobiprole in the BAL fluid. The penetration of the drug into the lung will be calculated. Four 1000mg administered every 8 hours

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
1
Inclusion Criteria
  • Informed Consent
  • Between 18 and 75 years of age inclusive
  • VAP - 48 hours after onset of mechanical ventilation
  • BMI 18 - 35 inclusive
  • Albumin < 3.3 g/dL or clinical evidence of edema
  • Negative Pregnancy test
  • Expected survival of at least 7 days
Exclusion Criteria
  • Renal impairment (CrCl < 80 mL/min)
  • Known drug allergy (including penicillin, cephalosporin, carbapenems, or other beta-lactams)
  • History of seizures
  • Sustained shock, unresponsive to sympathomimetics
  • Conditions that may have jeopardized adherence to the protocol (NYHA Class 4 cardiac disease, >15% total body burn or significant third degree burn)

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
CeftobiproleCeftobiproleCeftobiprole, 1 G q8h as 4 hour infusions for 2 days
Primary Outcome Measures
NameTimeMethod
Pharmacokinetics (to measure the levels of ceftobiprole in the blood and urine and tissues of the lungs) during dosing and 24 hours after last dose infused2 days
Secondary Outcome Measures
NameTimeMethod
Safety will be evaluated throughout the study.Study Duration
© Copyright 2025. All Rights Reserved by MedPath